Top Analyst Upgrades and Downgrades: AbbVie, Camping World, Cleveland-Cliffs, Coupa, Dollar General, DuPont, Nike, Roku, StoneCo and More

Nike Inc. (NYSE: NKE) was reiterated as Neutral and the price target was raised to $87 from $84 at UBS. Nike closed up 0.2% at $84.67 ahead of the call, and its consensus target price was $92.50. The 52-week range is $66.53 to $90.00.

ObsEva S.A. (NASDAQ: OBSV) was reiterated as Outperform with a $38 target price (versus a $9.73 close) at Wedbush. The firm noted that Nolasiban/IVF’s new data reinforces its bullish view, with Phase 3 study results due in the fourth quarter.

Papa John’s International Inc. (NASDAQ: PZZA) was started with a Buy rating and assigned a $70 target price (versus a $46.59 close) at Northcoast Research.

Roku Inc. (NASDAQ: ROKU) was reiterated as Buy and the price target was raised to $185 from $135 (versus a $156.88 close) at D.A. Davidson. Roku has a consensus target price of $119.87 and a 52-week trading range of $26.30 to $157.22.

StoneCo Ltd. (NASDAQ: STNE) was started with a Buy rating and assigned a $38 target price (versus a $30.09 close) at Guggenheim. This was Warren Buffett’s best performing stock of 2019, and its consensus target price was $34.67.

Thor Industries Inc. (NYSE: THO) was reiterated as Underperform and the price objective was lowered to $47 from $58 (versus a $44.22 close, after a 3.7% drop) at Merrill Lynch. It had a consensus analyst target of $70.90 ahead of this call, and its 52-week trading range is $42.05 to $109.94.

Viad Corp. (NYSE: VVI) was reiterated as Buy and the price target is $85 (versus a $64.63 close) at Janney. The firm called Viad its favorite stock of the type in its coverage universe as an overlooked growth story with the potential benefit of strategic options in the future.

World Wrestling Entertainment Inc. (NYSE: WWE) was reiterated as Neutral and the price target was lowered to $79 from $86 at Citigroup. Evercore ISI started coverage as Outperform with a $90 target price. Shares closed down almost 3% at $69.37 ahead of the calls, and the prior consensus target price was $97.33.

Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) was started with an Outperform rating and assigned a $38 target price (versus a $25.61 close) at Wedbush. The firm called it undervalued, based on its core and late-stage market opportunities supporting the current share price at a low-cost to no-cost option to label expansions and earlier-stage pipeline efforts.

If you are an income investor who just cannot stomach the low Treasury yields at this point (under 1.5% on the 10-year note), here are eight alternative investments to Treasury notes and bonds as the markets and yields stand at this point in 2019.

Wedbush has issued a report on the top regional banks and noted that the solid loan growth has been one of the few bright spots for the group this year. It has concerns over whether that loan growth can continue and sees a disconnect between positive borrower sentiment, strong loan pipelines and no signs of emerging credit deterioration, as well as how the media portrays the economy and the shape of the yield curve in particular. The report went on:

The fear is the headline risk of a recession turns into a self-fulfilling prophecy. That said, we maintain our cautious view of the bank group given the unfavorable rate environment, which has gotten worse since July with the precipitous drop in the 10-year treasury. Plus, a number of leading economic indicators are down from recent peak levels and most are in a downtrend, making us even more cautious on our 2020 outlook. … We lowered our EPS estimates for our entire bank group by 2% in 2020 and are below consensus on almost every bank.

Tuesday’s top analyst calls included Annaly Capital Management,, Enterprise Products Partners, Kinder Morgan, Lululemon Athletica, RealReal, Snap, Square, Under Armour and many more.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.